- Bristol Myers Squibb recently secured European Commission approval for Opdivo plus AVD as the first immunotherapy-based frontline regimen for advanced classical Hodgkin lymphoma in adults and adolescents, while also reporting late-breaking positive Phase 3 oncology data at ASCO 2026.
- Together, these developments highlight how Bristol Myers Squibb is broadening its oncology portfolio into earlier treatment settings and younger patients, potentially helping to counterbalance upcoming patent risks on older therapies.
- We’ll now examine how Opdivo’s new EU frontline approval for advanced Hodgkin lymphoma may reshape Bristol Myers Squibb’s broader investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Bristol-Myers Squibb Investment Narrative Recap
To own Bristol Myers Squibb today, you need to believe its newer oncology and cardiovascular drugs can gradually offset pressure from looming patent expiries and drug pricing headwinds. The new EU frontline Opdivo approval in advanced Hodgkin lymphoma reinforces that story but does not change the biggest near term risk, which is how sharply revenues could fall once core products like Eliquis and Opdivo lose exclusivity.
The most connected recent development is the FDA’s Priority Review of Camzyos for adolescents with obstructive hypertrophic cardiomyopathy. Together with Opdivo’s expanded Hodgkin lymphoma use in younger patients, it underscores how Bristol Myers Squibb is pushing key brands into earlier disease settings and broader age groups, which could be important for softening the impact of future patent cliffs and pricing pressure.
Yet, beneath these approvals, investors should still be watching how upcoming loss of exclusivity and tighter pricing rules could...
Read the full narrative on Bristol-Myers Squibb (it's free!)
Bristol-Myers Squibb's narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This requires a 6.2% yearly revenue decline and an earnings increase of about $1.3 billion from $7.3 billion today.
Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, a 16% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were assuming revenues would shrink to about US$37.4 billion by 2029 even before this Opdivo news, so if you are worried about execution risk in the pipeline you might find their more cautious narrative, which puts much more weight on harsh patent cliffs and pricing pressure, an important counterpoint to the view that new approvals like Opdivo plus AVD and Camzyos label expansions will be enough to fill the gap.
Explore 10 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 13% less than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com